1. Home
  2. Issue 6-1
  3. Report

advertisement

Topcon

Disclosure

Reviewers were asked the following:

My relationship to the industry regarding the material to be presented is as follows.
(Check all applicable items. List the specific relationships at the end.)

There is no industry connection to this material. I am a paid consultant, or have received honoraria or other compensation (e.g. travelling costs, speaker's fee) from a corporation that may be affected by this comment (positively or negatively). I am (or a member of my family is) a stockholder in a corporation that may be affected by this comment (positively or negatively).  I receive support from the industry for research related to the subject of my comment.
  • No conflict of interest for writing this comment/report in IGR
    Aihara; Anderson; Chew; Cioffi; Cordeiro; Crowston; Foster; Greenfield; Grigera; Harris; Harwerth; He; Hernandez; Johnson; Jonas; Konstas; Lindsey; Martin; Melamed; Mishima; Nizankowska; Palmberg; Perez Grossman; Pillunat; Ritch; Rojanapongpun; Schloetzer-Schrehardt; Tamm; Tezel; Wilson Roy
     
  • Disclosed:
    • Friedman: no conflict, but does consult to industry
    • Greve: Intensive contacts with: Alcon (1, 2), Allergan (1, 2), CZM (1,2), Haag-Streit (1, 2), Heidelberg (1, 2), LDT (1, 2), Medtronic (1, 2), Merck (1), Novartis (1), Pfizer (1, 2, 3), R-Tech Ueno (1, 2), Santen USA/JP (1, 2), Ziemer (1, 2);
      1 = WGA; 2 = IGR; 3 = consultant
    • Heijl: Consultant CZM, and Research and Travel support. More information will follow shortly
    • Hitchings: paid consultant or have received honoraria; stockholder. Both may be affected by this comment (positively or negatively)
    • Hollo: Consultant speaker (Pfizer, Alcon, Allergan), Research support (LDT)
    • Khaw: Cambridge Antibody Technology - Research support
    • Krieglstein: Consultant for Pfizer, no conflict with commentary
    • Levin: Received support from Industry for research related to the subject of comment
    • Michelson: Received support from industry related to the subject of my comment
    • Migdal: I am on the Allergan Glaucoma Advisory Board, a Merck Editorial Board, and Faculty Member for Alcon, Allergan, Merck and Pfizer. I currently receive research grants from Cambridge Antibody Technology (TGF beta study) and Allergan (Memantine)
    • Noecker: Speakers bureau (Lumenis, Alcon, Allergan), research support (L, All), Consultant (All, bimatoprost)
    • Pfeiffer: Consultant / Speaker for Pfizer, MSD, Alcon, Allergan
    • Wax: Full time Alcon employee, commentary does not pertain to a commercial product at this time
    • Wheeler: Employee Allergan
    • Zimmerman: Employee Pfizer, commentary does not pertain to a commercial product at this time.
       
  • Information still to come:
    Weinreb

Issue 6-1

Table of Contents Editor's Selection

Change Issue

advertisement

Oculus